HK1208628A1 - 用於肝臟疾病的預防劑或治療劑 - Google Patents

用於肝臟疾病的預防劑或治療劑

Info

Publication number
HK1208628A1
HK1208628A1 HK15109362.4A HK15109362A HK1208628A1 HK 1208628 A1 HK1208628 A1 HK 1208628A1 HK 15109362 A HK15109362 A HK 15109362A HK 1208628 A1 HK1208628 A1 HK 1208628A1
Authority
HK
Hong Kong
Prior art keywords
prophylactic
therapeutic agent
hepatic diseases
hepatic
diseases
Prior art date
Application number
HK15109362.4A
Other languages
English (en)
Inventor
宮崎徹
Original Assignee
Miyazaki Toru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miyazaki Toru filed Critical Miyazaki Toru
Publication of HK1208628A1 publication Critical patent/HK1208628A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
HK15109362.4A 2012-04-27 2015-09-24 用於肝臟疾病的預防劑或治療劑 HK1208628A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012103958 2012-04-27
PCT/JP2013/062469 WO2013162021A1 (ja) 2012-04-27 2013-04-26 肝疾患の予防または治療剤

Publications (1)

Publication Number Publication Date
HK1208628A1 true HK1208628A1 (zh) 2016-03-11

Family

ID=49483317

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109362.4A HK1208628A1 (zh) 2012-04-27 2015-09-24 用於肝臟疾病的預防劑或治療劑

Country Status (8)

Country Link
US (1) US9993524B2 (zh)
EP (1) EP2870970B1 (zh)
JP (1) JP6143015B2 (zh)
CN (1) CN104470531B (zh)
DK (1) DK2870970T3 (zh)
ES (1) ES2668507T3 (zh)
HK (1) HK1208628A1 (zh)
WO (1) WO2013162021A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102258677B1 (ko) * 2013-12-10 2021-06-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 간 질환의 감별 진단
US10349640B2 (en) 2014-02-07 2019-07-16 Toru Miyazaki Preventive or therapeutic agent for kidney disease
WO2016190387A1 (ja) * 2015-05-28 2016-12-01 国立大学法人東京大学 腫瘍の治療剤及びその使用
US10996217B2 (en) * 2015-08-06 2021-05-04 Sekisui Medical Co., Ltd. Method for examining renal disease
US20190317096A1 (en) * 2015-09-10 2019-10-17 Sekisui Medical Co., Ltd. Method for examining liver cancer
EP3595660B1 (en) * 2017-03-14 2023-07-05 SJT Molecular Research, SL Compounds for use in the prevention and/or treatment of non-alcoholic fat liver disease and non-alcoholic steatohepatitis
US11946937B2 (en) * 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
ES2974545T3 (es) * 2017-11-16 2024-06-27 Toru Miyazaki AIM variante
CN108535492B (zh) * 2018-03-27 2019-02-12 重庆医科大学 Aim作为生物标志物在诊断、预后或监测脓毒症中的用途
SG11202103250UA (en) 2018-10-01 2021-04-29 Toru Miyazaki Therapeutic agent for neurodegenerative disease
JP7315965B2 (ja) * 2018-11-09 2023-07-27 積水メディカル株式会社 ウィルス性肝癌の検出方法
WO2020158858A1 (ja) * 2019-01-31 2020-08-06 積水メディカル株式会社 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び対象におけるｎａｓｈの検出方法
EP3919903A4 (en) * 2019-01-31 2022-11-02 Sekisui Medical Co., Ltd. METHOD FOR IMMUNOLOGICAL ANALYSIS OF FREE AIM IN A BIOLOGICAL SAMPLE AND MEASUREMENT KIT
JP7159093B2 (ja) * 2019-03-26 2022-10-24 徹 宮崎 血中フリー体ａｉｍ増加用組成物
CN112116860B (zh) * 2020-10-23 2022-06-10 北京博医时代教育科技有限公司 用于上腹部手术训练的模型及其制作方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100331244A1 (en) * 2009-06-01 2010-12-30 The University Of Tokyo Pharmaceutical composition, food or drink, and methods related thereto
CN103648531A (zh) 2010-05-20 2014-03-19 宫崎彻 用于预防或治疗代谢综合症的方法

Also Published As

Publication number Publication date
EP2870970A4 (en) 2016-06-01
EP2870970B1 (en) 2018-02-21
EP2870970A1 (en) 2015-05-13
JPWO2013162021A1 (ja) 2015-12-24
CN104470531B (zh) 2018-01-12
ES2668507T3 (es) 2018-05-18
WO2013162021A1 (ja) 2013-10-31
DK2870970T3 (en) 2018-05-28
CN104470531A (zh) 2015-03-25
US20150094268A1 (en) 2015-04-02
US9993524B2 (en) 2018-06-12
JP6143015B2 (ja) 2017-06-07

Similar Documents

Publication Publication Date Title
HK1208628A1 (zh) 用於肝臟疾病的預防劑或治療劑
HK1203963A1 (zh) 新型治療藥物
HK1210031A1 (zh) 癡呆症治療藥或預防藥
GB201212513D0 (en) Therapeutic agents
EP2740482A4 (en) PROPHYLACTIC OR THERAPEUTIC FOR DISEASES OF THE MOUTH VALVE
HK1214144A1 (zh) 干眼症預防/治療劑
EP2913047A4 (en) SPECIFIC THERAPEUTIC AGENT OF PULMONARY DISEASE
HK1206620A1 (zh) 血脂異常症治療劑
EP2823830A4 (en) MESH-HIGHNESS MEDIUM
GB201217704D0 (en) Therapeutic agents
GB2525835B (en) Pharmaceutical agent
HK1219224A1 (zh) 角結膜病症的治療劑
HK1214152A1 (zh) 用於肌萎縮性側索硬化的治療劑
EP2815763A4 (en) REMEDIES FOR INFLAMMATORY DISEASES
EP2914267A4 (en) TREATMENT OF DARM CONSTIPATION
GB201223021D0 (en) Therapeutic agents
GB201212512D0 (en) Therapeutic agents
GB201210233D0 (en) Therapeutic agents
GB201214985D0 (en) Modified therapeutic agents
GB201213712D0 (en) Modified therapeutic agents
GB201108234D0 (en) Pharmaceutical agent